Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab PK/PD in Children with Severe Eosinophilic Asthma
NCT02377427Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of mepolizumab in severe eosinophilic asthma (SEA) (2 arms), sponsored by GSK. Primary endpoints: Maximum Plasma Concentration at Week 20, Area Under Concentration Time Curve at Week 20 and 5 more. Started Aug 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
severe eosinophilic asthma (SEA)
Beyond the preview
Go deeper on NCT02377427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377427.